Ivermectin Rx For COVID-19: Insurance Coverage Doesn’t Match Evidence

January 13, 2022

 • 

Read time:

<5 mins
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Doctor Sitting At Desk And Writing A Prescription For Her Patient
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print

Even though clinical trials haven’t shown it works against COVID-19, doctors continue to prescribe ivermectin – and a new study suggests health insurers are heavily subsidizing the cost of those prescriptions. The study’s authors call for insurers to align their coverage of the drug with the level of medical evidence surrounding it — just like they do for other medications, tests and procedures. The study, published in JAMA by a team from the University of Michigan and Boston University, uses insurance data to study how much health plans paid for oral ivermectin in late 2020 and early 2021. They found that plans paid 61% to 74% of the cost, or about $36 to $39 per prescription.

More from the Alumni Education Gateway
Join the Alumni Education Gateway Email List​
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.